Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Business Wire•26/10/2026•07:00 ET
0
Key Highlights
- ➤Varegacestat symptom score improved -1.50 versus +0.59 with placebo at week 48
- ➤Physical function improved +3.90 versus -3.04 with placebo at week 48
- ➤Confirmed ORR reached 56% versus 9% with placebo in RINGSIDE
- ➤Varegacestat cut progression or death risk 84% versus placebo
- ➤FDA accepted Immunome’s NDA; PDUFA target action date is April 28, 2027
Expert Statements
Bob Lechleider, M.D., Chief Medical Officer of Immunome
“For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.”
Bob Lechleider, M.D., Chief Medical Officer of Immunome
“These presentations build on the previously reported RINGSIDE results and offer additional insight into varegacestat’s potential to address the burden of this disease.”
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
* Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48
Get started
Create a free account to read the full story.